NYXOAH S.A.

Nyxoah shares climbed about 11.9% after the approval-relevant US ACCCESS study met the primary safety and efficacy endpoints in patients with complete concentric collapse. The Genio system showed an AHI responder rate of 77.2% (Full Analysis Set) and an ODI responder rate of 78.7%; no device-related serious adverse events occurred within 12 months. Nyxoah halted recruitment early and is preparing a PMA Supplement for the FDA to expand the indication; full 12-month data will be presented at the annual meeting of the International Surgical Sleep Society. » More on de.investing.com

Nyxoah opens the books for the quarter ended 30.06.2026; six analysts expect an EPS of -0.387 EUR versus -0.550 EUR a year earlier. Revenues for the past quarter are forecast at about 7.6 million EUR, an increase of 464% from 1.3 million EUR a year ago. For the current fiscal year the consensus estimates (nine analysts) are a loss of -1.176 EUR per share and revenues of around 37.3 million EUR versus 10.0 million EUR in the prior year. » More on finanzen.net

Nyxoah has completed an equity financing of $95 million and expects a second tranche of $15 million from an EIB loan by the end of June, bringing the total to $110 million. The funds are intended to support the commercial ramp-up of the Genio system for treating obstructive sleep apnea in the US. The stock is trading near its 52-week low at $1.31; analysts see potential undervaluation, but the company warns of rapid cash burn. » More on de.investing.com